Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression Erika Costa de AlvarengaWalison N. SilvaAlexander Birbrair Review Article 01 August 2018 Pages: 1749 - 1755
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients Marius BillJuliane GrimmSebastian Schwind Original Article 22 May 2018 Pages: 1757 - 1765
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia Luca MaurilloFrancesco BuccisanoAdriano Venditti Original Article 10 June 2018 Pages: 1767 - 1774
Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1 Huifei LiuSa A. WangGuilin Tang Original Article 05 June 2018 Pages: 1775 - 1783
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials Frédéric BaronMarian Stevens-KroefStefan Suciu Original Article 20 June 2018 Pages: 1785 - 1795
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy Laura CicconiMassimo BrecciaFrancesco Lo-Coco Original Article 27 June 2018 Pages: 1797 - 1802
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events Matteo MolicaEmilia ScalzulliMassimo Breccia Original Article 27 May 2018 Pages: 1803 - 1808
Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma Wen-Hao ZhangGao-Yang LiRong Tao Original Article 12 May 2018 Pages: 1809 - 1816
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP) Vincenzo PavoneAnna MeleSilvana Capalbo Original Article 27 July 2018 Pages: 1817 - 1824
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study Alexander EgleMichael SteurerRichard Greil Original Article Open access 04 June 2018 Pages: 1825 - 1839
Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma Jun-Ying NiuTian TianWei Xu Original Article 02 June 2018 Pages: 1841 - 1849
Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study Sung Yong OhWon Seog KimCheolwon Suh Original Article 11 June 2018 Pages: 1851 - 1857
Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales Birgit FedermannMartin R. MuellerFalko Fend Original Article 12 June 2018 Pages: 1859 - 1868
Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma Mukul AggarwalNarendra AgrawalDinesh Bhurani Original Article 21 May 2018 Pages: 1869 - 1877
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS Wioletta RomaniukLukasz BolkunJanusz Kloczko Original Article Open access 26 June 2018 Pages: 1879 - 1887
Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia Andreas TiedeAndrew Worster Original Article Open access 26 May 2018 Pages: 1889 - 1901
The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study Zara ForbriggerStefan KuhleKetan Kulkarni Original Article 30 May 2018 Pages: 1903 - 1908
Red blood cells metabolome changes upon treatment with different X-ray irradiation doses Fabio BaroniChiara MarracciniThelma A. Pertinhez Original Article 07 June 2018 Pages: 1909 - 1917
Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia Sezaneh HaghpanahTahereh ZareiMehran Karimi Original Article 21 June 2018 Pages: 1919 - 1924
The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network Paolo RicchiAntonella MeloniAlessia Pepe Original Article 21 June 2018 Pages: 1925 - 1932
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia Quan RenYa-Li ZhouXiao-Lin Yin Original Article 22 June 2018 Pages: 1933 - 1939
Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials Li WangCheng-ying ZhuChun-ji Gao Original Article 08 June 2018 Pages: 1941 - 1950
Outcome of gastrointestinal graft-versus-host disease according to the treatment response Masaharu TamakiHideki NakasoneYoshinobu Kanda Original Article 02 June 2018 Pages: 1951 - 1960
Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency—a case report and comprehensive review of the literature Alexander SimonisMichaela FuxAntonia M. S. Müller Original Article 13 June 2018 Pages: 1961 - 1973
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies Manar M. I. KhalilHans A. MessnerFotios V. Michelis Original Article 11 June 2018 Pages: 1975 - 1985
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study Ioanna SakellariEleni GavriilakiAchilles Anagnostopoulos Original Article 05 June 2018 Pages: 1987 - 1994
A portion of expanded granular lymphocytes cause pure white cell aplasia? Yasushi IsobeYu UemuraIkuo Miura Letter to the Editor Open access 02 May 2018 Pages: 1995 - 1997
Monotypic and IgH-rearranged lymphoplasmacytic cells restricted to the light zone of germinal centers: an early (in situ?) marginal zone lymphoma? Jennifer ChapmanFrancisco Vega Letter to the Editor 03 May 2018 Pages: 1999 - 2000
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine Greta ScapinelloMarco PizziFrancesco Piazza Letter to the Editor 04 May 2018 Pages: 2001 - 2003
Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis Stefano MolicaDiana GiannarelliTait D. Shanafelt Letter to the Editor 08 May 2018 Pages: 2005 - 2008
A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment Yuriko FujitaTomonori NakazatoTakehiko Mori Letter to the Editor 01 May 2018 Pages: 2009 - 2010
Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis Kelsey UminskiRajat KumarMatthew Seftel Letter to the Editor 01 May 2018 Pages: 2011 - 2012
Correction to: Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma Satoshi YamasakiDai ChiharaRitsuro Suzuki Correction 26 July 2018 Pages: 2013 - 2014